Auditor
@auditor112017
Followers
268
Following
3K
Media
456
Statuses
5K
Retired Internal Auditor (CISA), Accountant, and Info Sec Engineer. Followed biotech, pharma, banking and tech sectors for more than 25 years.
Joined October 2017
$sgmo $qure UniQure pauses Fabry gene therapy dosing in 2 groups after toxicities emerge https://t.co/vkOXeu9rlN
fiercebiotech.com
Two dose-limiting toxicities have been recorded in uniQure’s trial evaluating an investigational AAV gene therapy designed to treat the rare condition Fabry disease. | Two dose-limiting toxicities...
0
1
10
$ions $bcyc Conjugation to a transferrin receptor 1-binding Bicycle peptide enhances ASO and siRNA potency in skeletal and cardiac muscles https://t.co/gneULMUHXc
pmc.ncbi.nlm.nih.gov
Improving the delivery of antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs) to skeletal and cardiac muscles remains a pivotal task toward the broader application of oligonucleot...
0
0
5
$ions $biib Nature Medicine Publishes Results from the Pivotal DEVOTE Study of High-Dose Regimen of Nusinersen in Spinal Muscular Atrophy https://t.co/pgOgbM3Azj
finance.yahoo.com
Findings from DEVOTE support clinical benefits of the high-dose regimen of nusinersen (50 mg and 28 mg) in both treatment-naïve individuals and those previously treated with 12 mg nusinersenThe...
1
0
1
Would the $25m give $sgmo enough time to get some data from Nav 1.7? They need some positive data readout on Nav 1.7 to change the narrative.
0
0
6
There could be a possibility that $sgmo is not getting the high upfront that they are asking especially if its Astellas due to the very weak yen. Could be agreeing with a much lower upfront and have to streamline operations to make the funds last longer.
0
0
3
New streamlined processes are coming from FDA! $sgmo $ions https://t.co/4MFDJA7br0
0
0
2
$ions This is an amazing pipeline! Listing couple of follow-on drugs using siRNA with semi-annual dosing: ION775 and ION924
0
1
5
$ions $biib Biogen Receives European Commission Approval for High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy https://t.co/wNCF3Dcjew
0
0
0
Could 2026 be the year for $sgmo? https://t.co/fctxEpYZwa
cnbc.com
CNBC’s “Power Lunch” team discusses health care and pharma stocks as momentum in the sector builds with Jared Holz of Mizuho.
0
0
4
Will $sgmo be part of this M&A by big pharma?! https://t.co/XeLX0LieAL
cnbc.com
Michael Yee, global head of biotech research at UBS, joins CNBC’s ‘Squawk on the Street’ to explain why he is bullish on biopharma stocks this year, the pharma M&A outlook, and more.
0
0
6
If Grok's analysis on the potential of $IONS DMPK's ASO (MsPA+Bcyc conjugation) is correct, it would outperform the competition. https://t.co/Nme38j3H73
0
0
0
$ions Grok's best guess on MsPA efficacy on lung tissues. https://t.co/dWQbNLHp4N
0
0
0
$ions Grok on non-conjugated ASO using MsPA to the lung tissues. https://t.co/FXeVTa8DaO
2
0
2
$ions I was expecting mgmt to develop conjugated drugs for pulmonary targets. Looks like they are relying on their new backbone chem (MsPA) to over come the issues that they encountered from their previous failed attempt.
1
0
3
$ions Not sure if NMA tech includes MsPA chem. If not, competitors would have tough time catching up!
0
0
1